Semaglutide's Heart Benefits Extend to Heart Failure Patients, New Research Suggests

Strategic Insights -

New research has shown that the weight loss drug semaglutide, marketed under the brand names Wegovy and Ozempic, may have significant heart benefits for people with heart failure. A team of researchers from the University of London's Institute of Cardiovascular Science analyzed data from 4,286 people with heart disease, including those with heart failure, who were randomly assigned to take semaglutide or a dummy drug over an average of three years. The study found that semaglutide was linked to a 28% reduction in major adverse cardiac events, including heart attacks and strokes, compared to the dummy drug group. Specifically, the subgroup of people with pre-existing heart failure saw a 24% reduction in heart disease-related deaths and a 19% reduction in deaths from any cause.

Key Takeaways:

  • Semaglutide was found to be beneficial for people with heart failure, reducing major adverse cardiac events by 28%.
  • The drug was linked to a 24% reduction in heart disease-related deaths and a 19% reduction in deaths from any cause among people with pre-existing heart failure.
  • The benefits of semaglutide were similar regardless of type of heart failure, including reduced ejection fraction.
  • The drug's mechanism of action is not fully understood, but may include positive impacts on blood sugar, blood pressure, and inflammation, as well as direct effects on the heart muscle and blood vessels.
  • Researchers suggest that semaglutide may have the potential for other, as yet unknown, benefits.

Statistics:

  • 4,286 people with heart disease were analyzed in the study.
  • The average follow-up period was over three years.
  • Semaglutide was linked to a 28% reduction in major adverse cardiac events.
  • The subgroup of people with pre-existing heart failure saw:

+ 24% reduction in heart disease-related deaths

+ 19% reduction in deaths from any cause

  • 12.3% of the dummy drug group had major adverse cardiac events, compared to 9.1% of the semaglutide group.

Sources:

  • "Semaglutide and Cardiovascular Outcomes: An analysis of the SELECT trial" (The Lancet)
  • Additional reporting by PA
  • Novo Nordisk (study sponsor)